Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | TTR | P02766 | 1/20 | 0.52 |
| ▸ | DPP4 | P27487 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.49 |
| ▸ | ESR1 | P03372 | 7/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | SNCA | P37840 | 1/20 | 0.48 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.47 |
| ▸ | APP | P05067 | 4/20 | 0.42 |
| ▸ | P4HB | P07237 | 1/20 | 0.42 |
| ▸ | FDPS | P14324 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4253230 | 1.00 | CYP3A4 (0.53) | CYP3A4TTRDPP4CA12CA1 | |
| SCHEMBL4257997 | 0.90 | TTR (0.55) | CYP3A4TTRDPP4CA12CA1 | |
| SCHEMBL4258005 | 0.90 | TTR (0.55) | CYP3A4TTRDPP4CA12CA1 | |
| SCHEMBL4255130 | 0.88 | TTR (0.52) | CYP3A4TTRDPP4CA12CA1 | |
| SCHEMBL4257162 | 0.88 | TTR (0.52) | CYP3A4TTRDPP4CA12CA1 | |
| SCHEMBL4257157 | 0.88 | TTR (0.52) | CYP3A4TTRDPP4CA12CA1 | |
| SCHEMBL4255123 | 0.88 | TTR (0.52) | CYP3A4TTRDPP4CA12CA1 | |
| SCHEMBL4254773 | 0.85 | SNCA (0.48) | CYP3A4TTRESR1SNCAESR2 | |
| SCHEMBL4254770 | 0.85 | SNCA (0.48) | CYP3A4TTRESR1SNCAESR2 | |
| SCHEMBL4264973 | 0.85 | CYP3A4 (0.50) | CYP3A4TTRDPP4CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7569601-B2 | Cycloalkylidene compounds as modulators of estrogen receptor | SMITHKLINE BEECHAM CORPORATION (US) | 2009-08-04 | — | — | US | disclosed |
| US-20070213348-A1 | Chemical Compounds | BRITTON JONATHAN E | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213348-A1 | Chemical Compounds | GPER1, ESR2, ESR1 | CYP3A4 428/4885TTR 4866/4885DPP4 1371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.